alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>                     <C>                     
<PERIOD-TYPE>                     12-MOS                 12-MOS                 
<FISCAL-YEAR-END>                          SEP-30-1996             SEP-30-1997  
<PERIOD-START>                             OCT-01-1995             OCT-01-1996  
<PERIOD-END>                               SEP-30-1996             SEP-30-1997  
<CASH>                                          43,457                  59,840  
<SECURITIES>                                    18,601                  21,372  
<RECEIVABLES>                                    2,944                   7,751  
<ALLOWANCES>                                       649                   1,164  
<INVENTORY>                                        604                   1,079  
<CURRENT-ASSETS>                                69,668                  97,982  
<PP&E>                                           6,510                  13,560  
<DEPRECIATION>                                   2,971                   5,306  
<TOTAL-ASSETS>                                  73,207                 112,701  
<CURRENT-LIABILITIES>                           17,690                  33,546  
<BONDS>                                              0                       0  
<PREFERRED-MANDATORY>                                0                       0  
<PREFERRED>                                          0                       0  
<COMMON>                                        46,578                  56,367  
<OTHER-SE>                                           0                       0  
<TOTAL-LIABILITY-AND-EQUITY>                    73,207                 112,701
<SALES>                                         59,862                 100,775  
<TOTAL-REVENUES>                                59,862                 100,775  
<CGS>                                            8,708                  10,682  
<TOTAL-COSTS>                                    8,708                  10,682  
<OTHER-EXPENSES>                                37,584                  75,257  
<LOSS-PROVISION>                                     0                       0  
<INTEREST-EXPENSE>                                  79                      52  
<INCOME-PRETAX>                                 15,108                  18,302  
<INCOME-TAX>                                     4,612                   4,602  
<INCOME-CONTINUING>                             10,496                  13,700  
<DISCONTINUED>                                       0                       0  
<EXTRAORDINARY>                                      0                       0  
<CHANGES>                                            0                       0  
<NET-INCOME>                                    10,496                  13,700  
<EPS-PRIMARY>                                     0.41                    0.49  
<EPS-DILUTED>                                     0.36                    0.44  
        

</TABLE>
§ 582.5452 Manganese gluconate. ( a ) *Product.* Manganese gluconate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<PAGE>   1

                                                                       Exhibit 5


               LETTERHEAD OF BLACKWELL SANDERS PEPER MARTIN LLP




                                October 12, 1999


Illuminet Holdings, Inc.
P.O. Box 2909
4501 Intelco Loop, S.E.
Lacey, Washington 98503

Ladies and Gentlemen:

     We have acted as counsel to Illuminet Holdings, Inc. a Delaware corporation
(the "Company"), in connection with the proposed offering of up to (i) 3,800,000
shares of common stock of the Company, $.01 par value per share with attached
rights to purchase Series B Participating Cumulative Preference Stock (the
"Common Stock") issuable under the 1997 Equity Incentive Plan, as amended (the
"Equity Incentive Plan") (ii) 700,000 shares of Common Stock issuable under the
1999 Stock Purchase Plan (the "Stock Purchase Plan"), and (iii) 427,725 shares
of class A common stock of the Company, $.01 par value per share with attached
rights to purchase Series B Participating Cumulative Preference Stock (the
"Class A Common Stock") issuable under the Equity Incentive Plan.

     In connection with the foregoing, we have examined such documents,
corporate records and other instruments as we have deemed necessary or
appropriate in connection with this opinion. Based upon and subject to the
foregoing, we are of the opinion that when such shares of Common Stock and Class
A Common Stock have been issued and sold by the Company in accordance with the
terms of the Equity Incentive Plan and the Stock Purchase Plan, such shares will
constitute legally issued, fully paid and non-assessable shares of the Company.

     We consent to the filing of this opinion as an exhibit to the registration
statement pursuant to which such shares will be sold and to the reference to us
in such registration statement.

                                        Very truly yours,



                                        /s/ Blackwell Sanders Peper Martin LLP
                                        Blackwell Sanders Peper Martin

                                      -11-
5800

6600

5200

5800

5800

5600

5200

5800

6200

4800

5000

5600

5200

5800

5200

5200

5200

5600

4600

4800

5200

5400

6000

5200

5600

5800

5600

5600

5200

5200

6000

5600

5400

5400

5200

5800

6000

5400

5800

5400

6200

5400

4800

4800

5000

5000

5000

4800

5400

5000

C O U N T Y R D -C 011 C O U N T Y R D -C 011

Bear Creek

Bear Creek

Bear Creek

Bear Creek

Willow Creek

Bull Creek

Willow Creek

Bear Creek

Bear Creek

Alamo

Hueco

Black

Canyon

Wood

Canyon

Wood Canyon

Playas

Valley

Black

Canyon

Black

Canyon

Sentinel

Butte

Ala

m

o

H

u

e

c

o

M

o

u

ntain

s

Guano

Mine

Humble

Number 1

Humble

Number 1

McDauw's

Well

Lookout

Well

Mosse

Ranch

Eagle

Mountain

Horse

Mountain

Sentinel

Butte

U Bar

Ridge

Dog

Mountains

Pierce

Peak

Hilo

Peak

Sheridan

Canyon

Whitewater

Mountains

30"

7

47

75

550

34

000

43

34

108° 7

34

45

7 E

86

44

76

22'

79

7

34

140

39

108° 000m

30"

30"

75

7 7

85

30' 7 000 FEET

180

N

74

31°

80

34

7

34

25'

7

E

34

45

81

7

77

87

000m

22' 40 7 30" 7

30'

000m

34

25'

84

000

7

34

27'

25'

48

25'

34

34

108°

42

82

81

34

34

80

FEET

42

31°

27'

34

738 44

30'

2

38 000m

FEET

49

7

34

22' 7

27'

40

85

N

77

30"

78

22'

34

34

7

46

7

000 FEET

41

30"

34

78

49

31°

7

7

34

7

30"

82

30'

76

34

2

34

34

30"

41

86

34

83

108°

87

46

31° 7

34

34

39

34

43

83

34

27'

7

84

520

79

47

U.S. DEPARTMENT OF THE INTERIOR

U. S. GEOLOGICAL SURVEY

NEW MEXICO

ADJOINING 7.5' QUADRANGLES

QUADRANGLE LOCATION

SENTINEL BUTTE, NM

2010

Interstate Route State Route

ROAD CLASSIFICATION

Interstate Route US Route State Route

Ramp 4WD

US Route Local Road

SENTINEL BUTTE QUADRANGLE

NEW MEXICO

7.5-MINUTE SERIES

Zone 12R

North American Datum of 1983 (NAD83)

World Geodetic System of 1984 (WGS84). Projection and

1 000-meter grid: Universal Transverse Mercator,

Produced by the United States Geological Survey

10 000-foot ticks: New Mexico Coordinate System of 1983

(west zone)

Imagery...............................NAIP, January 2005 - May 2009

Roads..............................................©2006-2010 Tele Atlas

Names...............................................................GNIS, 2008

Hydrography.................National Hydrography Dataset, 2005

Contours............................National Elevation Dataset, 2001

1000 500 0 METERS 1000 2000

1000 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 10000

FEET

This map was produced to conform with version 0.5.10 of the

draft USGS Standards for 7.5-Minute Quadrangle Maps.

A metadata file associated with this product is draft version 0.5.11

SCALE 1:24 000

1 0.5 0 1

MILES

MN

1 0.5 0 KILOMETERS 1 2

GN

UTM GRID AND 2010 MAGNETIC NORTH DECLINATION AT CENTER OF SHEET

1° 20 ́

24 MILS

9° 38 ́

171 MILS

U.S. National Grid

100,000-m Square ID

Grid Zone Designation

12R

YV

CONTOUR INTERVAL 40 FEET

NORTH AMERICAN VERTICAL DATUM OF 1988
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE GULFWEST
OIL COMPANY'S QUARTERLY REPORT FILED ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30,
1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1
<CURRENCY>                    0
       
<S>                             <C>
<PERIOD-TYPE>                  6-MOS
<FISCAL-YEAR-END>              DEC-31-1997
<PERIOD-START>                 APR-1-1998
<PERIOD-END>                   JUN-30-1998
<EXCHANGE-RATE>                1
<CASH>                         0
<SECURITIES>                   0
<RECEIVABLES>                  588,290
<ALLOWANCES>                   0
<INVENTORY>                    0
<CURRENT-ASSETS>               725,482
<PP&E>                         22,598,245
<DEPRECIATION>                 3,435,655
<TOTAL-ASSETS>                 19,906,816
<CURRENT-LIABILITIES>          12,504,899
<BONDS>                        0
<PREFERRED-MANDATORY>          0
<PREFERRED>                    52
<COMMON>                       2,958 
<OTHER-SE>                     2,017,243  
<TOTAL-LIABILITY-AND-EQUITY>   19,906,816
<SALES>                        474874           
<TOTAL-REVENUES>               708,504
<CGS>                          0
<TOTAL-COSTS>                  1,311,964
<OTHER-EXPENSES>               0
<LOSS-PROVISION>               0
<INTEREST-EXPENSE>             (389,464)
<INCOME-PRETAX>                (992,924)
<INCOME-TAX>                   0        
<INCOME-CONTINUING>            (992,924)
<DISCONTINUED>                 0        
<EXTRAORDINARY>                0        
<CHANGES>                      0       
<NET-INCOME>                   (992,924)
<EPS-PRIMARY>                  (.58)
<EPS-DILUTED>                  (.58)
        


</TABLE>
T hi s di s pos i t i on i s notappr opr i a t e f orpubl i c a t i on and i s notpr e c e de nt * e xc e pta s pr ovi de d by9th C i r . R . 36- 3.

T he pa ne l una ni m ous l yc onc l ude s thi s c a s e i s s ui t abl e f orde c i s i on ** w ith o u t o r a l ar g u m e n t. See F ed. R . A pp . P . 34 (a )( 2). NOT F OR P UB L I CAT I ON UN I TE D STATE S C OU RT OF APPE ALS FOR T HE NI NTH CI RC UI T UN I T E D S T AT E S OF AME R I C A, P l ai nt i ff

- A pp el l ee , v. A LEX I S CH A V EZ- A RU J A S, D e f

e n d a n t - A p p e llan t. N o. 11- 10153 D . C . N o. 4: 10 -c r- 01 29 6-C K J- B P V -1 ME MOR AN DU M *

A pp ea l fr om the U ni t ed S t at es D i stri ctC ou rt

f orthe D i s tr i c tof

A r i z ona C i ndyK . J or ge ns on, D i s tr i c tJudge , P r e s i di ng

S ubm i tt e d Jul y17, 2012 ** B efo re: S C H R O E D E R , T H O M A S an dS IL V E R M A N , C i rcu i tJu d g es. A le x is C h a v e z - A ru

ja s ap p e a ls f

r o m h is g u ilty - p le ac o n v ic tio n a n d3 3 - m o n th se nt ence for bei ng an i l l egalal i en foun d i n the U ni t ed S t at es af t erhavi ng been pr e vi ous l yr e m ove d, i n vi ol a t i on of 8 U . S . C . § 1326( a ) . P ur s uantt o A nder s v . Ca lifo rn ia , 386 U . S . 738 ( 1967) , C ha ve z - A ruj a s ’ s c ouns e l ha s f i l e d abr i e f

s t a t i ng 

# FI LED JU L 19 2012 M OLLY C. DW Y ER, CLERK U . S. C O U R T OF APPE ALSW e dec l i ne t o revi ew C havez-A ruj as ’ s i neff ec t i ve as si st ance of coun se l 1 cl ai m because the re cord i s notsuff i ci ent l y devel op ed t o p erm i tre vi ew on di re ct ap p e a l. See U

n i ted Sta tes v. L ea su re , 31 9 F . 3d 10 92 , 10 99 (9th C i r. 20 03 ). 2 11- 10153 the r e a r e no gr ounds f

orr e l i e f , a l ong w i th am ot i on t o w i thdr aw a s c ouns e l of reco rd . W e h av e p ro v i d edth e ap p el l an tw i th th e o p p o rtu n i ty t o fi l e a p ro se supp l em ent albri ef

. N o p ro se supp l em ent albri ef or answ er i ng bri ef

has bee n f i l e d. O uri nde pe nde ntr e vi e w of the r e c or d pur s uantt o P e n s o n v . O h io , 4 8 8 U . S. 7 5 , 8 0 - 8 1 ( 1 9 8 8 ) , d is c lo s e s n o a r g u ab le g r o u n d s f o rr e lie f o n d ir e c t ap p e a l. W e 1 d is m is s in lig h t o f

th e v a lidap p e a l w a iv e r . See U ni ted States v. N

gu ye n , 235 F . 3d 11 79 , 11 82 (9th C i r. 20 00 ). C o u n sel ’ s m o t i o n t o w i th d raw i s GR AN T E D. DI S MI S S E D.
# C_2016402EN.01003901.xml

| 31.10.2016 | EN | Official Journal of the European Union | C 402/39 |
| --- | --- | --- | --- |

31.10.2016

EN

Official Journal of the European Union

C 402/39

---

Judgment of the General Court of 15 September 2016 — Herbert Smith Freehills v Council

(Case T-710/14) (1)

1

((Access to documents - Regulation (EC) No 1049/2001 - Documents relating to discussions preceding the adoption of the Directive on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products - Refusal to grant access - Exception relating to the protection of legal advice - Rights of the defence - Overriding public interest))

(2016/C 402/43)

Language of the case: English

Parties

Parties

Applicant: Herbert Smith Freehills LLP (London, United Kingdom) (represented by: P. Wytinck, lawyer)

Applicant:

Defendant: Council of the European Union (represented by: E. Rebasti, M. Veiga and J. Herrmann, acting as Agents)

Defendant:

Intervener in support of the defendant: European Commission (represented by: P. Van Nuffel, J. Baquero Cruz and F. Clotuche-Duvieusart, acting as Agents)

Intervener in support of the defendant

Re:

Re:

Application based on Article 263 TFEU and seeking annulment of Decision 18/c/01/14 of the Council of 23 July 2014, refusing access to certain documents relating to the adoption of Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products and repealing Directive 2001/37/EC (OJ 2014 L 127, p. 1).

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Herbert Smith Freehills LLP to bear its own costs and to pay those incurred by the Council of the European Union; |
| --- | --- |

2.

Orders Herbert Smith Freehills LLP to bear its own costs and to pay those incurred by the Council of the European Union;

| 3. | Orders the European Commission to bear its own costs. |
| --- | --- |

3.

Orders the European Commission to bear its own costs.

---

(1)  OJ C 409, 17.11.2014.

1

---
EXHIBIT 32

                   CERTIFICATION OF PERIODIC FINANCIAL REPORT
                       PURSUANT TO 18 U.S.C. SECTION 1350

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, each of the undersigned officers of AMCOL
International Corporation (the "Company") certifies that the quarterly report on
Form 10-Q of the Company for the three and nine months ended September 30, 2005
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 and information contained in that Form 10-Q fairly
presents, in all material respects, the financial condition and results of
operations of the Company.


Date: November 4, 2005                  /s/ Lawrence E. Washow
                                        ----------------------------------------
                                        Lawrence E. Washow
                                        Chief Executive Officer


Date: November 4, 2005                  /s/ Gary L. Castagna
                                        ----------------------------------------
                                        Gary L. Castagna
                                        Chief Financial Officer
<PAGE>   1
 
                                                                   EXHIBIT 23.02
 
               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
 
     We consent to the reference to our firm under the caption "Experts" and to
the use of our report dated February 6, 1998 (except for the second paragraph of
Note 1, as to which the date is December 21, 1998) with respect to the financial
statements of Anergen, Inc. included in the Registration Statement on Form S-4
and related Prospectus of Corixa Corporation for the registration of shares of
its common stock.
 
                                              ERNST & YOUNG LLP
 
Palo Alto, California
December 22, 1998
<PAGE>   1



COMPUTATION OF PER SHARE EARNINGS                              EXHIBIT 11


The computation of primary earnings per share is as follows:


                                   Three Months Ended
                                      December 31,
                                   ------------------
                                    1996       1995
                                    ----       ----
Weighted average shares
outstanding                      4,802,762  5,183,259


Add equivalent shares for
stock options (a)                  899,922    892,834
                                 ---------  ---------
Average shares outstanding for
computation of primary earnings
per share                        5,702,684  6,076,093
                                 =========  =========

Income from continuing
operations                      $  682,000 $  883,000
                                ========== ==========

Net Income                      $  682,000 $  890,000
                                ========== ========== 



PRIMARY EARNINGS PER COMMON SHARE:
 
From continuing operations          $  .12     $  .15
                                    ======     ======

Net Income                          $  .12     $  .15
                                    ======     ====== 





(a) Computed under the "Treasury Stock Method" using the average market price
    for the respective period.












                                 Page 14 of 16
# C_2016016EN.01003302.xml

| 18.1.2016 | EN | Official Journal of the European Union | C 16/33 |
| --- | --- | --- | --- |

18.1.2016

EN

Official Journal of the European Union

C 16/33

---

Judgment of the General Court of 25 November 2015 — bd breyton-design v OHIM (RACE GTP)

(Case T-520/14) (1)

1

((Community trade mark - Application for Community word mark RACE GTP - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009))

(2016/C 016/41)

Language of the case: German

Parties

Parties

Applicant: bd breyton-design GmbH (Stockach, Germany) (represented by: T Raab and H. Lauf, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A Schifko, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 27 March 2014 (Case R 1230/2013-1) concerning an application for registration of the word sign RACE GTP as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders bd breyton-design GmbH to pay the costs. |
| --- | --- |

2.

Orders bd breyton-design GmbH to pay the costs.

---

(1)  OJ C 303, 8.9.2014.

1

---
§ 520.35 Afoxolaner, moxidectin, and pyrantel. ( a ) *Specifications.* Each chewable tablet contains 9.375 milligrams (mg) afoxolaner, 45 micrograms (mcg) moxidectin, and 18.75 mg pyrantel; 18.75 mg afoxolaner, 90 mcg moxidectin, and 37.5 mg pyrantel; 37.5 mg afoxolaner, 180 mcg moxidectin, and 75 mg pyrantel; 75 mg afoxolaner, 360 mcg moxidectin, and 150 mg pyrantel; or 150 mg afoxolaner, 720 mcg moxidectin, and 300 mg pyrantel.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer orally once a month at the minimum dose of 1.14 mg/lb (2.5 mg/kg) afoxolaner, 5.45 mcg/lb (12 mcg/kg) moxidectin, and 2.27 mg/lb (5.0 mg/kg) pyrantel. For heartworm disease prevention, give once monthly for at least 6 months after last exposure to mosquitoes.
( 2 ) *Indications for use in dogs.* For the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment and control of adult hookworm (*Ancylostoma caninum, Ancylostoma braziliense,* and *Uncinaria stenocephala*) and roundworm (*Toxocara canis* and *Toxascaris leonina*) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*) and the treatment and control of *Ixodes scapularis* (black-legged tick), *Rhipicephalus sanguineus* (brown dog tick), *Dermacentor variabilis* (American dog tick), and *Amblyomma americanum* (lone star tick) infestations for 1 month in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[88 FR 84699, Dec. 6, 2023]
<PAGE>

                                                                    EXHIBIT 13.2

                                  CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350,
           AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         I, Bjorn Olafsson, as Executive Vice President and Chief Financial
Officer of Nera ASA (the "Company"), certify, pursuant to 18 U.S.C.ss. 1350, as
adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

         (1)      the accompanying annual report on Form 20-F for the period
                  ended December 31, 2003 of the Company, as filed with the U.S.
                  Securities and Exchange Commission (the "Report"), fully
                  complies with the requirements of Section 13(a) or 15(d) of
                  the Securities Exchange Act of 1934, as amended; and

         (2)      the information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.

Dated: June 25, 2004

                                           /s/ Bjorn Olafsson
                                           ----------------------------------
                                           Bjorn Olafsson
                                           Executive Vice President and Chief
                                           Financial Officer

         A signed original of this written statement required by Section 906 has
been provided to the Company and will be retained by the Company and furnished
to the U.S. Securities and Exchange Commission or its staff upon request.

         The foregoing certification is being furnished solely to accompany this
Report pursuant to 18 U.S.C. ss. 1350, and is not being filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be
incorporated by reference into any filing of the Company, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.
#### § 801.119 In vitro diagnostic products.

A product intended for use in the diagnosis of disease and which is an in vitro diagnostic product as defined in § 809.3(a) of this chapter shall be deemed to be in compliance with the requirements of this part and section 502(f)(1) of the Federal Food, Drug, and Cosmetic Act if it meets the requirements of subpart B of this part and the requirements of § 809.10 of this chapter.

[78 FR 58820, Sept. 24, 2013]